BIOMAT Database Logo BIOMAT Database Logo

[Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia]. 1990

W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Z Katedry i Kliniki Alergologii i Chorób Wewnetrznych AM, Zakładu Biofarmacji Studium Farmaceutycznego CMKP w Byd goszczy.

Therapeutical efficacy was clinically evaluated in 21 patients with ventricular cardiac arrhythmias. The drug was given orally with preceded intramuscular dose. Therapeutic effect was verified by the measurements of procainamide and N-acetylprocainamide concentrations in blood serum to determine the minimal effective concentration of the drug required to obtain satisfactory antiarrhythmic effect. Procainamide proved effective in cardiac arrhythmias in 14 patients (66.7%) with statistical significance in the acute myocardial infarctions; blood serum procainamide plus N-acetylprocainamide levels being were below the therapeutical range. The poor correlation of the dose of the drug and respective procainamide, N-acetylprocainamide concentrations in blood was observed. Relationship of the therapeutical effects blood serum level of the drug should be estimated basing of the assays of both procainamide and N-acetylprocainamide .

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011342 Procainamide A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Procaine Amide,Apo-Procainamide,Biocoryl,Novocainamide,Novocamid,Procainamide Hydrochloride,Procamide,Procan,Procan SR,Procanbid,Pronestyl,Rhythmin,Amide, Procaine,Hydrochloride, Procainamide
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000120 Acecainide A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure. Acetylprocainamide,Acecainide Hydrochloride,Acecainide Monohydrochloride,N-Acetylprocainamide,Hydrochloride, Acecainide,Monohydrochloride, Acecainide,N Acetylprocainamide
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014693 Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST. Fibrillation, Ventricular,Fibrillations, Ventricular,Ventricular Fibrillations

Related Publications

W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide.
January 1985, The American journal of cardiology,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
September 1989, Journal of cardiovascular pharmacology,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
N-Acetyl-procainamide kinetics in the elderly.
April 1981, Clinical pharmacology and therapeutics,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
N-acetyl procainamide causing torsades de pointes.
December 1982, The American journal of cardiology,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Analysis for procainamide and N-acetyl procainamide in plasma or serum by high-performance liquid chromatography.
January 1977, Clinical chemistry,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Improved semi-automated analysis of procainamide and N-acetyl procainamide utilizing a totally volatile mobile phase.
January 1981, Journal of analytical toxicology,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Serum procainamide levels as therapeutic guides.
January 1977, Clinical pharmacokinetics,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
[Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
September 1980, Schweizerische medizinische Wochenschrift,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.
June 1981, The Journal of pharmacology and experimental therapeutics,
W Sinkiewicz, and A Marzec, and A Jankowski, and A Hoffmann, and K Makuch, and B Romański
Acetylation of procainamide and isoniazid by a rat liver-N-acetyl-transferase.
January 1981, European journal of drug metabolism and pharmacokinetics,
Copied contents to your clipboard!